米国の組織診断市場2021-2028:技術・製品別(IHC、一次・特殊染色)、用途別(乳がん、NSCLC)

◆英語タイトル:U.S. Tissue Diagnostics Market Size, Share & Trends Analysis Report By Technology & Product (IHC, Primary & Special Staining), By Application (Breast Cancer, NSCLC), And Segment Forecasts, 2021 - 2028
◆商品コード:GV21JU044
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年6月11日
◆ページ数:157
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:米国
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥684,250見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥799,250見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,029,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、米国の組織診断市場規模が2028年までに28.1億ドルに達すると予測しています。2021年から2028年までに年平均3.91%成長する見通しです。本市場調査レポートは、組織診断の米国市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、技術・製品別分析、用途別分析、企業情報などを徹底分析したものです。
【レポートの概要】

U.S. Tissue Diagnostics Market Growth & Trends
The U.S. tissue diagnostics market size is estimated to reach USD 2.81 billion by 2028, registering a CAGR of 3.91% over the forecast period, according to a new report by Grand View Research, Inc. Pivotal factors supplementing the market growth include continuous rise in the cases of cancer, growth in organ transplantation & donation, and increased acceptance toward personalized medicine & companion diagnostics in the U.S. Increase in the number of research activities targeted toward the development of novel tissue diagnostics solutions is also expected to drive the market.

The field of anatomic pathology has witnessed a paradigm shift, which can be attributed to the exponential growth in cancer incidence in the U.S., thereby expanding the clinical pathology industry. Also, steady convergence of molecular pathology with anatomic pathology, steep adoption of novel biopsies for cancer detection, and integration of digital technologies is expected to collaboratively make a positive impact on market growth.

Tissue analysis provides significant information, which is difficult to understand using conventional molecular techniques. Currently, companion diagnostic tests are rapidly being adopted by pharmaceutical companies for obtaining first-line therapy designations/approvals for their products. In addition, their use in the identification of patient cohorts, which are likely to benefit from targeted therapeutics, has increased the significance of tissue diagnostics in the development of precision medicine.

In addition, the field of tissue diagnostics has witnessed gradual evolution with the introduction of upgraded technologies, including Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Immunofluorescence (IF), comparative genomic hybridization, and Next-Generation Sequencing (NGS). Key players are focused on identifying novel biomarkers and developing assays for advanced cancer diagnosis. Furthermore, companies are conducting biomarker pathologist training programs to boost the adoption rate of modern pathological solutions.

U.S. Tissue Diagnostics Market Report Highlights

• The IHC segment held the highest revenue share of over 28% in 2020. The segment’s dominance is attributed to the wide acceptance of IHC across clinical laboratories for different workflows

• These workflows include tissue examination targeted toward disease prognosis and anticipating therapeutic response among patients with cancer

• The digital pathology segment is anticipated to register the fastest CAGR during the forecast period mainly due to heavy investments in infrastructure as well as an onsite server for image digitization

• In addition, the lack of skilled pathologists has propelled the demand for automated systems in disease diagnosis, thereby boosting the segment growth

• An increase in the prevalence of breast cancer along with the launch of novel products dedicated to breast cancer detection have led to the dominance of this application segment

• Moreover, the advent of genomic technologies aimed at gaining a better understanding of the genetic markup of a tumor is further offering lucrative growth opportunities to companies

• The market players are investing significantly in novel product development and acquisition of small players to increase their revenue share

【レポートの目次】

Table of Contents

Chapter 1 Methodology And Scope
1.1 Research Assumptions
1.2 Research Methodology
1.3 Information Procurement
1.4 Information or Data Analysis
1.5 Market Formulation and Validation
1.6 U.S. Market: CAGR Calculation
1.7 Objectives
1.7.1 Objective 1:
1.7.2 Objective 2:
Chapter 2 Executive Summary
2.1 Segment Outlook
2.2 Market Summary
Chapter 3 U.S. Tissue Diagnostics Market: Market Variables, Trends, And Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Market Trends & Outlook
3.3 Market Dynamics
3.3.1 Market Drivers Analysis
3.3.1.1 Emerging solutions pertaining to digital tissue diagnostics
3.3.1.2 Advancements in imaging techniques and increasing affordability of diagnostics
3.3.1.3 Growth of personalized therapeutics and diagnostics
3.3.2 Market restraint Analysis
3.3.2.1 Presence of non-value based reimbursement policy and high costs associated with usage of tissue diagnosis
3.4 COVID-19 Impact Analysis
3.5 Penetration & Growth Prospect Mapping for Applications, 2020
3.6 U.S Tissue Diagnostics Market-SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.7 Industry Analysis – Porter’s
Chapter 4 U.S. Tissue Diagnostics Market: Technology & Product Business Analysis
4.1 U.S. Tissue Diagnostics Market: Technology & Product Movement Analysis
4.2 Immunohistochemistry
4.2.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry, 2017 – 2028 (USD Million)
4.2.2 Instruments
4.2.2.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry instruments, 2017 – 2028 (USD Million)
4.2.2.2 Slide Staining Systems
4.2.2.2.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry slide staining systems, 2017 – 2028 (USD Million)
4.2.2.3 Tissue Microarrays
4.2.2.3.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry tissue microarrays, 2017 – 2028 (USD Million)
4.2.2.4 Tissue Processing Systems
4.2.2.4.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry tissue processing systems, 2017 – 2028 (USD Million)
4.2.2.5 Slide Scanners
4.2.2.5.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry slide scanners, 2017 – 2028 (USD Million)
4.2.2.6 Other Products
4.2.2.6.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry other products, 2017 – 2028 (USD Million)
4.2.3 Consumables
4.2.3.1 U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry consumables, 2017 – 2028 (USD Million)
4.2.3.2 Reagents
4.2.3.2.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry reagents, 2017 – 2028 (USD Million)
4.2.3.3 Antibodies
4.2.3.3.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry antibodies, 2017 – 2028 (USD Million)
4.2.3.4 Kits
4.2.3.4.1 The U.S. tissue diagnostics market estimates and forecast for Immunohistochemistry kits, 2017 – 2028 (USD Million)
4.3 In situ Hybridization
4.3.1 The U.S. tissue diagnostics market estimates and forecast for In Situ Hybridization (ISH), 2017 – 2028 (USD Million)
4.3.2 Instruments
4.3.2.1 The U.S. tissue diagnostics market estimates and forecast for ISH instruments, 2017 – 2028 (USD Million)
4.3.3 Consumables
4.3.3.1 The U.S. tissue diagnostics market estimates and forecast for ISH consumables, 2017 – 2028 (USD Million)
4.3.4 Software
4.3.4.1 The U.S. tissue diagnostics market estimates and forecast for ISH software, 2017 – 2028 (USD Million)
4.4 Primary & Special Staining
4.4.1 The U.S. tissue diagnostics market estimates and forecast for Primary & special staining, 2017 – 2028 (USD Million)
4.4.2 H&E Staining
4.4.2.1 The U.S. tissue diagnostics market estimates and forecast for H&E Staining, 2017 – 2028 (USD Million)
4.4.3 Special Staining
4.4.3.1 The U.S. tissue diagnostics market estimates and forecast for SPECIAL Staining, 2017 – 2028 (USD Million)
4.5 Digital Pathology and Workflow
4.5.1 The U.S. tissue diagnostics market estimates and forecast for Digital pathology and workflow, 2017 – 2028 (USD Million)
4.5.2 Whole Slide Imaging
4.5.2.1 The U.S. tissue diagnostics market estimates and forecast for whole slide imaging, 2017 – 2028 (USD Million)
4.5.3 Image Analysis Informatics
4.5.3.1 The U.S. tissue diagnostics market estimates and forecast for image analysis informatics, 2017 – 2028 (USD Million)
4.5.4 Information Management System Storage & Communication
4.5.4.1 U.S. tissue diagnostics market estimates and forecast for information management system storage & communication, 2017 – 2028 (USD Million)
4.6 Anatomic Pathology
4.6.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology, 2017 – 2028 (USD Million)
4.6.2 Instruments
4.6.2.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology instruments, 2017 – 2028 (USD Million)
4.6.2.2 Microtomes &Cryostat Microtomes
4.6.2.2.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology microtomes & cryostat microtomes, 2017 – 2028 (USD Million)
4.6.2.3 Tissue Processors
4.6.2.3.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology tissue processors, 2017 – 2028 (USD Million)
4.6.2.4 Automatic Strainers
4.6.2.4.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology automatic strainers, 2017 – 2028 (USD Million)
4.6.2.5 Other Products
4.6.2.5.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology other products, 2017 – 2028 (USD Million)
4.6.3 Consumables
4.6.3.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology consumables, 2017 – 2028 (USD Million)
4.6.3.2 Reagents &Antibodies
4.6.3.2.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology reagents & antibodies, 2017 – 2028 (USD Million)
4.6.3.3 Probes &Kits
4.6.3.3.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology probes & kits, 2017 – 2028 (USD Million)
4.6.3.4 Others
4.6.3.4.1 The U.S. tissue diagnostics market estimates and forecast for Anatomic pathology others, 2017 – 2028 (USD Million)
Chapter 5 U.S. Tissue Diagnostics Market: Application Business Analysis
5.1 U.S. Tissue Diagnostics Market: Application Analysis
5.2 Breast Cancer
5.2.1 The U.S. Tissue Diagnostics Market estimates and forecast for Breast Cancer, 2017 – 2028 (USD Million)
5.3 Non-Small Cell Lung Cancer (NSCLC)
5.3.1 The U.S. Tissue Diagnostics Market estimates and forecast for Non-Small Cell Lung Cancer (NSCLC), 2017 – 2028 (USD Million)
5.4 Prostate Cancer
5.4.1 The U.S. Tissue Diagnostics Market estimates and forecast for prostate cancer, 2017 – 2028 (USD Million)
5.5 Gastric Cancer
5.5.1 The U.S. Tissue Diagnostics Market estimates and forecast for Gastric Cancer, 2017 – 2028 (USD Million)
5.6 Other Cancers
5.6.1 The U.S. Tissue Diagnostics Market estimates and forecast for Other Cancers, 2017 – 2028 (USD Million)
Chapter 6 Company Profile
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles
6.3.1 Merck KGaA
6.3.1.2 Company overview
6.3.1.2.1 Bio Reliance
6.3.1.2.2 Sigma-Aldrich Co. LLC
6.3.1.3 Financial Performance
6.3.1.4 Product benchmarking
6.3.1.5 Strategic initiatives
6.3.2 Thermo Fisher Scientific, Inc.
6.3.2.1 Company overview
6.3.2.1.1 Life Technologies Corporation
6.3.2.1.2 Affymetrix, Inc.
6.3.2.2 Financial Performance
6.3.2.3 Product benchmarking
6.3.2.4 Strategic initiatives
6.3.3 F. Hoffmann-La Roche Ltd
6.3.3.1 Company overview
6.3.3.2 Financial Performance
6.3.3.3 Product benchmarking
6.3.3.4 Strategic initiatives
6.3.4 Abbott Laboratories
6.3.4.1 Company overview
6.3.4.1.1 Alere
6.3.4.2 Financial Performance
6.3.4.3 Product benchmarking
6.3.4.4 Strategic initiatives
6.3.4.4.1 Strategic initiatives (Alere)
6.3.5 Siemens Healthineers AG
6.3.5.1 Company overview
6.3.5.2 Financial Performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 Danaher
6.3.6.1 Company overview
6.3.6.1.1 Beckman Coulter, Inc.
6.3.6.2 Financial Performance
6.3.6.3 Product benchmarking
6.3.6.4 Strategic initiatives
6.3.7 bioMérieux SA
6.3.7.1 Company overview
6.3.7.2 Financial Performance
6.3.7.3 Product benchmarking
6.3.7.4 Strategic initiatives
6.3.8 QIAGEN
6.3.8.1 Company overview
6.3.8.2 Financial Performance
6.3.8.3 Product benchmarking
6.3.8.4 Strategic initiatives
6.3.9 Becton, Dickinson & Company (BD)
6.3.9.1 Company overview
6.3.9.2 Financial Performance
6.3.9.3 Product benchmarking
6.3.9.4 Strategic initiatives
6.3.10 Agilent Technologies, Inc.
6.3.10.1 Company overview
6.3.10.2 Financial Performance
6.3.10.3 Product benchmarking
6.3.10.4 Strategic initiatives
6.3.11 General Electric Company (GE Healthcare)
6.3.11.1 Company overview
6.3.11.1.1 Cytiva
6.3.11.2 Financial Performance
6.3.11.3 Product benchmarking
6.3.11.4 Strategic initiatives
6.3.12 BioGenex
6.3.12.1 Company overview
6.3.12.2 Financial Performance
6.3.12.3 Product benchmarking
6.3.12.4 Strategic initiatives
6.3.13 Cell Signaling Technology, Inc.
6.3.13.1 Company overview
6.3.13.2 Financial Performance
6.3.13.3 Product benchmarking
6.3.13.4 Strategic initiatives
6.3.14 Bio SB
6.3.14.1 Company overview
6.3.14.2 Financial Performance
6.3.14.3 Product benchmarking
6.3.14.4 Strategic initiatives
6.3.15 DiaGenic ASA
6.3.15.1 Company overview
6.3.15.2 Product benchmarking
6.3.16 Sakura Finetek Japan CO., LTD.
6.3.16.1 Company overview
6.3.16.2 Financial Performance
6.3.16.3 Product benchmarking
6.3.16.4 Strategic initiatives
6.3.17 Abcam plc
6.3.17.1 Company overview
6.3.17.2 Financial Performance
6.3.17.3 Product benchmarking
6.3.17.4 Strategic initiatives
6.3.18 Enzo Life Sciences, Inc.
6.3.18.1 Company overview
6.3.18.2 Financial Performance
6.3.18.3 Product benchmarking
6.3.18.4 Strategic initiatives
6.3.19 VITRO SA (Master Diagnóstica)
6.3.19.1 Company overview
6.3.19.2 Financial Performance
6.3.19.3 Product benchmarking
6.3.19.4 Strategic initiatives
6.3.20 TissueGnostics GmbH
6.3.20.1 Company overview
6.3.20.2 Financial Performance
6.3.20.3 Product benchmarking

List of Tables

Table 1 CPT codes for IHC (CBR201610)
Table 2 Comparative analysis of ISH software
Table 3 Commonly used special stains in microbiology applications
Table 4 Commonly used special stains in detection of nucleic acids
Table 5 Multipurpose special stains
Table 6 Expanding applications of tissue examinations
Table 7 The U.S. tissue diagnostics market estimates and forecast, by technology& product, 2017 - 2028 (USD Million)
Table 8 The U.S. tissue diagnostics market estimates and forecast, by immunohistochemistry, 2017 - 2028 (USD Million)
Table 9 The U.S. tissue diagnostics market estimates and forecast, by immunohistochemistry consumables, 2017 - 2028 (USD Million)
Table 10 The U.S. tissue diagnostics market estimates and forecast, by immunohistochemistry instruments, 2017 - 2028 (USD Million)
Table 11 The U.S. tissue diagnostics market estimates and forecast, by ISH, 2017 - 2028 (USD Million)
Table 12 The U.S. tissue diagnostics market estimates and forecast, by anatomic pathology, 2017 - 2028 (USD Million)
Table 13 The U.S. tissue diagnostics market estimates and forecast, by anatomic pathology consumables, 2017 - 2028 (USD Million)
Table 14 The U.S. tissue diagnostics market estimates and forecast, by anatomic pathology instruments, 2017 - 2028 (USD Million)
Table 15 The U.S. tissue diagnostics market estimates and forecast, by digital pathology instruments, 2017 - 2028 (USD Million)
Table 16 The U.S. tissue diagnostics market estimates and forecast, by application, 2017 - 2028 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Market segmentation and scope
Fig. 10 Market summary, 2020 (USD Million)
Fig. 11 Related/ancillary market outlook
Fig. 12 Market trends & outlook
Fig. 13 Market driver relevance analysis (Current & future impact)
Fig. 14 Traditional pathology workflow vs. digital pathology workflow
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Penetration & growth prospect mapping for applications, 2020
Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 18 Porter’s Five Forces Analysis
Fig. 19 The U.S. tissue diagnostics market: Technology & product outlook and key takeaways
Fig. 20 The U.S. tissue diagnostics market: Technology & product movement analysis
Fig. 21 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry, 2017 - 2028 (USD Million)
Fig. 22 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry instruments, 2017 - 2028 (USD Million)
Fig. 23 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry slide staining systems, 2017 - 2028 (USD Million)
Fig. 24 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry tissue microarrays, 2017 - 2028 (USD Million)
Fig. 25 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry tissue processing systems, 2017 - 2028 (USD Million)
Fig. 26 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry slide scanners, 2017 - 2028 (USD Million)
Fig. 27 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry other products, 2017 - 2028 (USD Million)
Fig. 28 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry consumables, 2017 - 2028 (USD Million)
Fig. 29 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry reagents, 2017 - 2028 (USD Million)
Fig. 30 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry antibodies, 2017 - 2028 (USD Million)
Fig. 31 The U.S. tissue diagnostics market estimates and forecast for immunohistochemistry kits, 2017 - 2028 (USD Million)
Fig. 32 The U.S. tissue diagnostics market estimates and forecast for in situ hybridization (ISH), 2017 – 2028 (USD Million)
Fig. 33 The U.S. tissue diagnostics market estimates and forecast for ISH instruments, 2017 - 2028 (USD Million)
Fig. 34 The U.S. tissue diagnostics market estimates and forecast for ISH consumables, 2017 - 2028 (USD Million)
Fig. 35 The U.S. tissue diagnostics market estimates and forecast for ISH software, 2017 - 2028 (USD Million)
Fig. 36 The U.S. tissue diagnostics market estimates and forecast for primary & special staining, 2017 - 2028 (USD Million)
Fig. 37 Troubleshooting of H&E staining, Part A
Fig. 38 Troubleshooting of H&E staining, Part B
Fig. 39 The U.S. tissue diagnostics market estimates and forecast for H&E staining, 2017 - 2028 (USD Million)
Fig. 40 The U.S. tissue diagnostics market estimates and forecast for special staining, 2017 - 2028 (USD Million)
Fig. 41 The U.S. tissue diagnostics market estimates and forecast for digital pathology and workflow, 2017 - 2028 (USD Million)
Fig. 42 The U.S. tissue diagnostics market estimates and forecast for whole slide imaging, 2017 - 2028 (USD Million)
Fig. 43 The U.S. tissue diagnostics market estimates and forecast for image analysis informatics, 2017 - 2028 (USD Million)
Fig. 44 The U.S. tissue diagnostics market estimates and forecast for information management system storage & communication, 2017 - 2028 (USD Million)
Fig. 45 The U.S. tissue diagnostics market estimates and forecast for anatomic pathology, 2017 - 2028 (USD Million)
Fig. 46 The U.S. tissue diagnostics market estimates and forecast for anatomic pathology instruments, 2017 - 2028 (USD Million)
Fig. 47 The U.S. tissue diagnostics market estimates and forecast for anatomic pathology microtomes & cryostat microtomes, 2017 - 2028 (USD Million)
Fig. 48 The U.S. tissue diagnostics market estimates and forecast for anatomic pathology tissue processors, 2017 - 2028 (USD Million)
Fig. 49 The U.S. tissue diagnostics market estimates and forecast for anatomic pathology automatic strainers, 2017 - 2028 (USD Million)
Fig. 50 U.S. tissue diagnostics market estimates and forecast for anatomic pathology other products, 2017 - 2028 (USD Million)
Fig. 51 The U.S. tissue diagnostics market estimates and forecast for anatomic pathology consumables, 2017 - 2028 (USD Million)
Fig. 52 The U.S. tissue diagnostics market estimates and forecast for anatomic pathology reagents & antibodies, 2017 - 2028 (USD Million)
Fig. 53 The U.S. tissue diagnostics market estimates and forecast for anatomic pathology probes & kits, 2017 - 2028 (USD Million)
Fig. 54 The U.S. tissue diagnostics market estimates and forecast for anatomic pathology others, 2017 - 2028 (USD Million)
Fig. 55 The U.S. tissue diagnostics market: Application definitions & scope
Fig. 56 The U.S. tissue diagnostics market: Application analysis
Fig. 57 Breast cancer statistics, U.S., 2020
Fig. 58 The U.S. tissue diagnostics market estimates and forecast for breast cancer, 2017 - 2028 (USD Million)
Fig. 59 Liquid biopsy vs tissue biopsy: NSCLC diagnostics
Fig. 60 The U.S. tissue diagnostics market estimates and forecast for non small cell lung cancer (NSCLC), 2017 - 2028 (USD Million)
Fig. 61 The U.S. tissue diagnostics market estimates and forecast for prostate cancer, 2017 - 2028 (USD Million)
Fig. 62 The U.S. tissue diagnostics market estimates and forecast for gastric cancer, 2017 - 2028 (USD Million)
Fig. 63 The U.S. tissue diagnostics market estimates and forecast for other cancers, 2017 - 2028 (USD Million)
Fig. 64 Strategy framework
Fig. 65 Market participation categorization

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[米国の組織診断市場2021-2028:技術・製品別(IHC、一次・特殊染色)、用途別(乳がん、NSCLC)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆